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Abstract: Solitary plasmacytoma and extramedullary plasmocytoma are tumors of 
malignant character composed of plasma cells, with a mean age of onset at 60 years. They 
can appear anywhere where the reticuloendothelial system is present. Usually these 
tumors lead to the development of multiple myeloma in a period of time ranging from 3 
to 5 years. We present a rare case handled in our neurosurgery service associated with an 
unusually long period of evolution. 
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Introduction 
Multiple myeloma (MM) is defined as 
neoplastic proliferation of plasma cells that 
make monoclonal protein in most cases. The 
paraprotein can be found in serum or urine. 
These lesions extend to extramedullar areas 
where bone destruction occurs. One of the 
entities that may arise in the context of MM is 
plasmacytoma, correlating with a more 
aggressive course of the disease. Diagnosis is 
based on clinical symptoms, imaging findings, 
serum immunoglobulin electrophoresis, and 
lab studies demonstrating end organ damage 
(hypercalcemia, anemia, and renal 
insufficiency). Diagnosis is confirmed by 
histopathologic analysis following tissue 
biopsy or bone marrow aspirate. We present 
the case of a patient with a giant frontal lesion, 
which was consistent with a plasmacytoma 
associated with long period of evolution. 
Case report 
Male patient, 47-yo, from rural area, with 
history of been working in palm oil production, 
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fishing and construction for several years. Is 
admitted to our institution referred from a first 
level care center, because of the presence of a 
large frontal lesion associated with head trauma 
30 years ago, which was gradually increasing in 
size. The patient referred dyspnea on moderate 
exercise and fatigue. On examination, the 
patient was in regular conditional, afebrile, 
hydrated, hemodynamically compensated, 
normal vital signs, a lesion protrude in the 
medial frontal region, 15 x 15 cms (Figures 1A 
and B) soft at touch; no lymphadenopathy, 
cardiopulmonary, abdomen and extremities 
were normal. It was decided to perform skull 
radiography, head CT-scan (Figures 2, 3A, 3B). 
Images were evaluated, and we decided to 
perform frontal craniotomy with tumor 
resection. Patient developed mediate and 
immediate satisfactory postoperative course. 
During ICU stance the patient status declines, 
developing hyperazoemia. The pathology 
report was consistent with a lesion composed of 
plasma cells. The nephrology service establishes 
the diagnosis of renal failure; the patient 
progressed without improvement and died 
from respiratory complications. 
 
 
 
 
 
 
Figure 1 - Head deformation; A. Lateral view and B. 
Frontal view of the patient head, showing a large, oval 
frontal lesion 
 
 
Figure 2 - Lateral plain cranial radiography showing 
multiple bone lesions in the frontal area of the skull 
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Figure 3 - Head CT-scan, A. axial slides showing a 
large, circular lesion located on the frontal pole, 
compromising frontal hemispheres bilaterally, but 
also the frontal bone, protruding through it, and 
bulking the scalp. B. Bone window, showing the large 
bone defect caused by the tumor 
Discussion 
Plasmocytoma is a rare entity that arises 
from malignant proliferation of B-cell line 
(non-Hodking lymphoma). Malignant plasma 
cell tumors include: extramedullary 
plasmocytoma (EP); solitary plasmocytoma of 
the bone (SPB); multifocal form of multiple 
myeloma; MM; and plasmablastic sarcoma.  
Unlike MM, SPB is a localized disease of 
plasma cells in bone formation without 
systemic complications. Intracranial 
plasmocytoma account for only 4% of all 
primary plasma cell tumors, with a conversion 
rate to MM occurring in approximately 50% of 
reported cases, (1) and in those patients with 
diagnosis of MM, intracranial EP as metastatic 
spread of MM occurs in 1% of reported cases. 
(2) SPB comprises 4% of all plasma cell 
malignancies, they are characterized by bone 
erosion, and EP arises in submucosal layer of 
tissues without bone involvement. Plasma cell 
neoplasms can histologically mimic a large 
variety of tumors (e.g., carcinomas, 
lymphomas, leukemia, plasma cell 
granulomas, sarcomas and histiocytic lesions). 
In fact, they are cytologically and 
immunophenotypically identical. The 
distinction between the various plasma cell 
neoplasms is based on clinical and radiological 
features. (3) Immunocytochemical study with 
antibodies to κ and λ light chains is a useful 
evaluation tool for a suspected plasmacytoma 
to distinguish it from a reactive proliferation. 
(3) 
The diagnosis of SPB or EP is made by the 
presence of a single plasmacytoma in the bone 
or the soft tissue and the absence of clinical, 
histologic, and radiological evidence of 
multiple myeloma; (4) they have a mean age of 
presentation of about 10 years younger than 
those who develop MM. (4)  
Most patients with plasma cell neoplasms 
present initially with vague symptoms, such as 
bone pain, anemia, or fatigue. The first 
rational approach for differential diagnosis of 
the SPB or EP is the exclusion of other plasma 
cell dyscrasias and, particularly dissemination 
of the disease into MM. This evaluation 
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requires complete blood count with white cell 
differential, erythrocyte sedimentation rate, 
serum calcium, phosphorous, blood urea 
nitrogen, creatinine, serum and urine protein 
electrophoresis, bone marrow biopsy, chest 
radiograph, and a radiographic skeletal survey. 
(5) Skeletal survey may detect lytic lesions, 
compression fractures (pathological), and 
osteopenia in areas with hemopoietically 
active bone marrow (vertebrae, ribs, femur, 
humerus, pelvis, sternum, and skull). (4–6) 
Bone marrow biopsy is required to detect 
malignant, plasmacytosis >10% is suggestive 
of MM.6 Regard the serum protein 
electrophoresis, it shows a sharp spike called 
the M component (M for monoclonal). When 
present, elevation of creatinine and uric acid is 
indicative of impaired renal function due to 
blockage of renal tubules by paraproteins and 
increased tumor load. The systemic search 
must persist for at least a year after the 
discovery of an intracranial plasmacytoma, 
especially if the mass is located in the skull 
base. (7)  
Treatment 
Some difficulties limit the correct approach 
of treatment for these patients, especially for 
the small number of patients and the lack of 
controlled trials with statistically significant 
results, making that treatment of choice stills 
doubtful. Radiotherapy is the most accepted 
therapeutic strategy; other treatment choices 
are surgery, the combination of radiotherapy 
and surgery, and chemotherapy. (5) SPB and 
EP are optimally treated with complete 
surgical resection plus external radiation 
therapy. (7) Local control of solitary EP in the 
head and neck seems to be improved when the 
dose to the clinical target volume is <45 Gy, a 
minimum dose of 45 Gy should be 
recommended. (8) Chemotherapy forms the 
mainstay of treatment of MM. The 
employment of chemotherapy 
(cyclophosphamide, vincristine, adriamycin, 
and dexamethasone) in combination with 
autologous peripheral blood stem cell 
transplant and interferons provides good 
quality of life, almost for 5 to 7 years. (9) For 
refractory or relapse cases while undergoing 
the above regimens, thalidomide and 
dexamethasone or high-dose dexamethasone 
is used.  
Surgical treatment is limited to adjuvant 
therapy and bone complications. Currently 
there are supported minimally invasive 
procedures for prophylactic fixation of 
fractures, spinal cord decompression when 
indicated, and treatment of pathological 
fractures. (10) Gong et al., (11) reported the 
similar case of SPB in skull. CT scan revealed 
an 8 cm × 9 cm osteolytic lesion on the scalp of 
skull with a well demarcated margin. A cake-
like mass was revealed at CT soft tissue 
window. The mass was completely excised. 
The level of response to treatment, and in 
particular, the complete response, is associated 
with better long-term results. These patients 
should be followed every three months to 
assess the appearance of new signs or 
symptoms of disease; and note that survival 
solitary plasmacytoma is longer than multiple 
myeloma patients in the absence of diffuse 
abnormalities in the bone marrow, kidney 
lesions and calcium metabolism.  
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The main prognostic indicator for SPB and 
EP is the progression to MM, being the cranial 
base location the strongest predictor for that 
progression. (7) Tumoral recurrence varies 
between 10% and 22%. (12) Factors associated 
with high risk for local recurrence are the 
initial size of tumor (diameter >5 cm), age of 
patient (>60 years), the incompleteness of 
treatment, and an initial increase of serum 
proteins. (5) 
Conclusions 
Plasmatic cell tumors are a rare disease, 
representing less than 1% of tumors of the 
head and neck. Usually they come from the 
brain parenchyma, or from dural or bone 
infiltration. Sometimes this type of injury is 
associated with MM. This last fact is the 
rationale for differential diagnosis of the SPB 
or EP is the exclusion of other plasma cell 
dyscrasias. Unlike MM, SPB and EP are 
localized disease of plasma cells without 
commitment systemic complications such as 
renal failure, hematological disorders, 
neurological and immunological. Pain and 
bone destruction with pathological fractures 
represent the most common clinical signs of 
this disease; therefore sometimes lab results 
are similar to MM as calcium disorders, renal 
dysfunction and increased beta-2 
microglobulin; plasmacytoma therefore has a 
better prognosis than MM. 
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